|Mr. Nigel Lange||CEO, MD & Director||388.26k||N/A||N/A|
|Mr. Christian Dal Cin||CFO & Company Secretary||N/A||N/A||N/A|
|Dr. Ralph Peters||Chief Medical Officer||N/A||N/A||N/A|
|Mr. David Turner||Head of Medical Affairs||N/A||N/A||N/A|
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
OncoSil Medical Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.